Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028656 | 0.84 | CYP17A1 (0.42) | SIRT2CYP17A1 | |
| SCHEMBL313034 | 0.78 | CYP17A1 (0.43) | SIRT2CYP17A1 | |
| SCHEMBL312882 | 0.78 | CYP17A1 (0.43) | SIRT2CYP17A1 | |
| SCHEMBL312834 | 0.75 | KDM4E (0.37) | SIRT2 | |
| SCHEMBL14249054 | 0.75 | SIRT2 (0.34) | SIRT2 | |
| SCHEMBL4034127 | 0.74 | CYP17A1 (0.43) | SIRT2CYP17A1 | |
| SCHEMBL4029531 | 0.74 | CYP17A1 (0.56) | SIRT2CYP17A1 | |
| SCHEMBL1414878 | 0.74 | CYP17A1 (0.43) | SIRT2CYP17A1 | |
| SCHEMBL4023825 | 0.73 | CYP17A1 (0.40) | SIRT2CYP17A1 | |
| SCHEMBL4025489 | 0.70 | CYP3A4 (0.42) | SIRT2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093403-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-10 | — | — | US | disclosed |
| US-20100105922-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105922-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | CYP17A1, HSD17B7, HSD17B1 | SIRT2 3756/4885CYP17A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.